We are live on ! Find out more
VRTX icon

Vertex Pharmaceuticals
VRTX

1,519 hedge funds and large institutions have $90.8B invested in Vertex Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 143 funds opening new positions, 550 increasing their positions, 617 reducing their positions, and 156 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more call options, than puts

Call options by funds: $846M | Put options by funds: $533M

8% less first-time investments, than exits

New positions opened: 143 | Existing positions closed: 156

3% less funds holding

Funds holding: 1,559 → 1,519 (-40)

3.23% less ownership

Funds ownership: 93.81% → 90.59% (-3.2%)

11% less repeat investments, than reductions

Existing positions increased: 550 | Existing positions reduced: 617

15% less capital invested

Capital invested by funds: $107B → $90.8B (-$16.4B)

56% less funds holding in top 10

Funds holding in top 10: 16 → 7 (-9)

Holders
1,519
Holders Change
-40
Holders Change %
-2.57%
% of All Funds
19.94%
Holding in Top 10
7
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-56.25%
% of All Funds
0.09%
New
143
Increased
550
Reduced
617
Closed
156
Calls
$846M
Puts
$533M
Net Calls
+$313M
Net Calls Change
-$63.9M

Top Buyers

1
Capital International Investors
Capital International Investors
California
+$858M
2
ClearBridge Investments
ClearBridge Investments
New York
+$467M
3
JP Morgan Chase
JP Morgan Chase
New York
+$236M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$218M
5
Capital Research Global Investors
Capital Research Global Investors
California
+$186M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.3B
2
Capital World Investors
Capital World Investors
California
-$1.18B
3
Jennison Associates
Jennison Associates
New York
-$1.13B
4
Edgewood Management
Edgewood Management
Connecticut
-$404M
5
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$326M
Name Holding Trade Value Shares
Change 		Change in
Stake
MW
1601
MBL Wealth
North Carolina
– -$241K -542 Closed
FWA
1602
FSM Wealth Advisors
Ohio
– -$247K -538 Closed
SP
1603
Stonebrook Private
Michigan
– -$237K -532 Closed
CFG
1604
Carr Financial Group
Massachusetts
– -$235K -528 Closed
IIA
1605
Integral Investment Advisors
California
– -$234K -525 Closed
FOA
1606
Five Oceans Advisors
California
– -$233K -523 Closed
AHL
1607
Abel Hall LLC
Louisiana
– -$232K -521 Closed
VAG
1608
VisionPoint Advisory Group
Texas
– -$232K -520 Closed
TFA
1609
Teamwork Financial Advisors
Texas
– -$231K -519 Closed
MFGM
1610
Marshall Financial Group (Maryland)
Maryland
– -$235K -512 Closed
MPM
1611
MBB Public Markets
Illinois
– -$227K -510 Closed
UAML
1612
US Asset Management LLC
Pennsylvania
– -$226K -507 Closed
DE
1613
Diversified Enterprises
Delaware
– -$225K -505 Closed
AFA
1614
Arlington Financial Advisors
California
– -$223K -500 Closed
MG
1615
McHugh Group
Ohio
– -$223K -500 Closed
MCM
1616
Mengis Capital Management
Oregon
– -$223K -500 Closed
GAG
1617
GM Advisory Group
New York
– -$222K -499 Closed
BFA
1618
Beaumont Financial Advisors
Massachusetts
– -$221K -496 Closed
LAM
1619
Lewis Asset Management
California
– -$220K -495 Closed
WPC
1620
Waters Parkerson & Co
Louisiana
– -$218K -489 Closed
BTW
1621
Boston Trust Walden
Massachusetts
– -$216K -485 Closed
LIM
1622
Loudon Investment Management
New Hampshire
– -$216K -485 Closed
RCA
1623
Roberts Capital Advisors
Colorado
– -$216K -485 Closed
AC
1624
AXQ Capital
New Jersey
– -$215K -484 Closed
FMTC
1625
Farmers & Merchants Trust Company
California
– -$215K -484 Closed
63 64
65
66 67

VRTX Hedge Fund Activity: Q3 2025 in Review

1,519 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2025, worth a combined $90.8B — down 15% from $107B a quarter earlier.

Sellers outnumbered buyers: 156 funds closed out of VRTX and 143 opened new positions — a net loss of 13 holders — while 617 trimmed existing stakes and 550 added.

The largest buyer was Capital International Investors, adding an estimated $858M. The largest seller was Fidelity Investments, cutting an estimated $1.3B.

  • 1,519 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2025, down from 1,559 in Q2 2025.
  • Funds reported $90.8B of Vertex Pharmaceuticals stock for Q3 2025, down 15% quarter-over-quarter.
  • 143 funds opened new Vertex Pharmaceuticals positions in Q3 2025 and 156 closed out, a net change of -13 holders.
  • The largest Vertex Pharmaceuticals buyer in Q3 2025 was Capital International Investors, an estimated $858M added.
  • The largest Vertex Pharmaceuticals seller in Q3 2025 was Fidelity Investments, an estimated $1.3B sold.

Based on aggregated 13F filings for Q3 2025.